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Regular Article
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• CK2b facilitates inositol
triphosphate–mediated
increase of cytosolic Ca21
and is essential for platelet
activation in arterial
thrombosis in vivo.
Platelets, anucleated megakaryocyte (MK)-derived cells, play a major role in hemostasis
andarterial thrombosis. Althoughprotein kinase casein kinase2 (CK2) is readily detected
in MKs and platelets, the impact of CK2-dependent signaling on MK/platelet (patho-)
physiology has remained elusive. The present study explored the impact of the CK2
regulatory b-subunit on platelet biogenesis and activation. MK/platelet-specific genetic
deletion of CK2b (ck2b2/2) in mice resulted in a significant macrothrombocytopenia and
an increased extramedullarmegakaryopoiesiswith an enhancedproportionof premature
platelets. Although platelet life span was only mildly affected, ck2b2/2 MK displayed an
abnormal microtubule structure with a drastically increased fragmentation within bone
marrow and a significantly reduced proplatelet formation in vivo. In ck2b2/2 platelets,
tubulin polymerization was disrupted, resulting in an impaired thrombopoiesis and an
abrogated inositol 1,4,5-triphosphate receptor–dependent intracellular calcium (Ca21)
release. Presumably due to a blunted increase in the concentration of cytosolic Ca21,
activation-dependent increases of a and dense-granule secretion and integrin aIIbb3
activation, and aggregation were abrogated in ck2b2/2 platelets. Accordingly, thrombus
formation and stabilization under high arterial shear rates were significantly diminished, and thrombotic vascular occlusion in vivo
wassignificantlyblunted inck2b2/2mice, accompaniedbyaslight prolongationof bleeding time. Following transientmiddle cerebral
artery occlusion, ck2b2/2 mice displayed significantly reduced cerebral infarct volumes, developed significantly less neurological
deficits, and showed significantly better outcomes after ischemic stroke than ck2bfl/fl mice. The present observations reveal CK2b
as a novel powerful regulator of thrombopoiesis, Ca21-dependent platelet activation, and arterial thrombosis in vivo. (Blood. 2017;
130(25):2774-2785)
Introduction
Platelets are small, anucleated cells derived from proplatelets, which
are generated by polyploid megakaryocytes (MKs) within sinusoids of
the bone marrow (BM).1 Microtubules, polarized tubular filaments of
a- and b-tubulin heterodimers, are the major structural components
involved in proplatelet formation.2,3 Polymerization of microtubules
is necessary to support the enlarging proplatelet mass.4,5 b1-Tubulin
expression is restricted in the MK/platelet lineage and is essential for
late MK differentiation and platelet biogenesis.6 Genetic loss of
b1-tubulin, the major b-tubulin isoform in MKs, results in macro-
thrombocytopenia due to pathological MK fragmentation, impaired
proplatelet formation, and release of large, immature platelets with an
attenuated response to activation.6,7
Themicrotubule plus end-binding protein 3 (EB3) transiently binds
to growing polymerized microtubules by recognizing the GTP-bound
state of b-tubulin.3,8,9 EB3 provides an essential hub for assembly
of plus-end-tracking proteins that facilitate interactions of micro-
tubules with the endoplasmic reticulum (ER).8,10 The ER is the
major intracellular calcium (Ca21) store in platelets and is continu-
ously remodeled through its interactions with microtubules.11 Inositol
1,4,5-triphosphate receptors (IP3Rs) within ER membranes facilitate
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rapid Ca21 release from internal stores on binding of Inositol 1,4,5-
triphosphate (IP3) generated in activated platelets.
12,13 Clustering of
IP3Rs in the ER membranes is essential for IP3R activity and
intracellular Ca21 release.14,15 Microtubule cytoskeleton dynamics
are crucial to IP3R clustering and IP3R-driven release of Ca
21 from
internal stores.8,16,17Microtubule-associated EB3 binds to IP3Rs, thus
promoting IP3R clustering and Ca
21 release.8
Platelet adhesion, activation, and aggregation are essential for
primary hemostasis, but are also critically involved in acute arterial
thrombotic occlusion, leading to myocardial infarction or ischemic
stroke.18 Moreover, platelets participate in the orchestration of vascular
inflammation andatherogenesis.19,20 Subendothelial collagen, collagen-
related peptide (CRP), and thrombin are the main triggers of platelet
activation, characterized by granule release, integrin aIIbb3 activation,
aggregation, and consecutive thrombus formation.12,21All those platelet
responses depend on a rapid increase in the concentration of cytosolic
Ca21 ([Ca21]i), which is accomplished by IP3-mediated Ca
21 release
from intracellular stores triggering subsequent extracellular Ca21 influx
via the stimulation of Orai1-mediated store-operated Ca21 entry.22
Casein kinase 2 (CK2) is a constitutively active serine-threonine
protein kinase with a tetrameric structure, in which 2 regulatory
b-subunits dimerize to link the 2 catalytic subunits a or a9.23 By
bridging the 2 catalytic subunits, CK2b is required for the assembly of
tetramericCK2complexes, thus enhancingCK2holoenzymestability to
modulate catalytic activity and substrate specifity.24-26 The regulatory
CK2 b-subunit plays an essential role in development because ubiq-
uitous Ck2b-deficiency in mice causes lethality before embryonic
day 7.5.27 CK2 controls various cellular processes, such as cell cycle
progression, proliferation, apoptosis, and signal transduction, involving
phosphatidylinositol 3-kinase (PI3K)/Akt andJAK/STATpathways in a
number of human cancers, including hematological malignancies.28
Recently, cell-specific deletion of CK2b in regulatory T cells identified
CK2 as an important modulator of immune response.29 Growing
evidence points to an important role of CK2 in the maintenance of cell
morphology as well as in the regulation of tubulin cytoskeleton and
microtubule dynamics.23,25,30 Although CK2 is strongly expressed in
platelets,31 its role in thrombopoiesis as well as platelet activation and
platelet-dependent arterial thrombosis still remains poorly defined.
The present study explored the role of CK2b in MK and platelet
biology as well as its impact on platelet biogenesis and function. To
circumvent prenatal death and to investigate the MK/platelet-specific
effects of CK2b on mechanisms regulating thrombopoiesis, hemosta-
sis, and arterial thrombosis in vivo, mice expressing ck2b alleles
flanked with the loxP-Cre excision sequence (cskn2bfl/fl) were used to
achieve MK/platelet-specific deletion of ck2b (ck2b2/2).
Material and methods
Mice
CK2b-floxed mice (csnk2bfl/fl) were generated by Thierry Buchou (INSERM,
Grenoble, France). Origin, breeding, and genotyping of csnk2bfl/fl mice were
described previously.27 For platelet-specific deletion of CK2b, cskn2bfl/fl mice
were crossed with PF4-Cre mice (The Jackson Laboratory) to obtain csnk2bfl/fl
pf4-Cre1 (ck2b2/2) and cskn2bfl/fl pf4-Cre– (ck2bfl/fl) littermates. Mice were
studied at the age of 6 to 12 weeks. All animal experiments were performed
according to the German animal protection law and were in accordance with the
recently publishedAnimal Research: Reporting In Vivo Experiments guidelines
(National Centre for the Replacement, Refinement and Reduction of Animals
in Research) and approved by the local authorities. Animal handling and care
complied with published regulations by the German law for the protection of
animals, and experiments were approved by the local authorities (Regier-
ungspräsidium Tübingen).
Methods
Platelet preparation, in vitro differentiation, and cultivation of fetal liver– and
BM-derived MKs, platelet and MK immunoblot analysis, determination of
reticulated platelets, platelet life span assay, determination of thrombopoietin
(TPO) levels and analysis of thrombopoiesis after TPO treatment, immunohis-
tochemistry of murine BM and spleens, immunofluorescence staining on
femora cryosections and cultured MKs, ultrastructural transmission electron
microscopy (TEM) analysis ofMKs, determination ofMK ploidy,multiphoton
intravital microscopy analysis of in vivo proplatelet formation, microtubule
sedimentation, real-time polymerase chain reaction, spectrofluorometry for
Ca21 measurements, flow cytometry, platelet aggregometry and adenosine
triphosphate (ATP) release, in vitro thrombus formation and stabilization, tail
bleeding time, invivo thrombus formation inmesenteric arterioles and in carotid
arteries, ischemic stroke in mice (transient middle cerebral artery occlusion
[tMCAO]), and the statistical analysis are described in detail in supplemental
Material and methods, available on the BloodWeb site.
Results
Genetic deletion of CK2b results in embryonic lethality in mice.
Therefore, to specifically delete ck2b in theMKlineage, cskn2bfl/flmice
were crossed with transgenic mice expressing Cre-recombinase under
the control of theMK- and platelet-specific platelet factor 4 (Pf4-Cre) to
obtain csnk2bfl/flpf4-Cre1 (ck2b2/2) and cskn2bfl/flpf4-Cre2 (ck2bfl/fl)
littermates. Real-time polymerase chain reaction analysis revealed that
CK2b was totally ablated in ck2b2/2 platelets on the transcript level,
whereas CK2b expression in other tissues was unaffected (Figure 1A;
supplemental Figure 1). Immunoblotting confirmed that platelets and
MKs derived from ck2b2/2 mice completely lacked CK2b protein
abundance (Figure 1B). Ck2b2/2 mice were viable and fertile, but,
notably, mice with the ck2b-deficient MK lineage developed distinct
macrothrombocytopenia without obvious signs of spontaneous hem-
orrhage. Macrothrombocytopenia in ck2b2/2 mice was reflected by a
reduction of platelet counts of 55% and a significant increase in platelet
volume (Figure 1C). To examine whether the macrothrombocytopenia
in ck2b2/2mice resulted from increased platelet turnover, platelet life
spanwas determined in ck2b2/2mice. Clearance of ck2b-null platelets
was only moderately accelerated, which may have contributed to, but
does not fully explain, the severely reduced platelet counts of ck2b2/2
mice (Figure 1D). Further, according to the determination of major
surface glycoproteins by flow cytometric analysis (Table 1), CK2b
deficiency resulted in a mildly but significantly reduced expression of
von Willebrand factor (vWF) receptor complex subunits, whereas the
expression of other surface receptors was comparable in ck2b2/2 and
ck2bfl/fl platelets.
The significant thrombocytopenia that was observed despite the
onlymoderately reducedplatelet life spanpromptedus toassessplatelet
production. To this end, we labeled blood samples ex vivo with thia-
zole orange. As revealed by flow cytometry, we found a significantly
higher amount of larger young reticulated platelets in ck2b2/2 mice
(Figure 1E). Because TPO is the main trigger of (compensatory)
megakaryopoiesis and its plasma concentrations are reciprocally regu-
lated by total platelet mass, we measured plasma TPO levels in
thrombocytopenic ck2b2/2 mice. TPO concentrations were slightly
but significantly increased in ck2b2/2mice (Figure 1F). TPO injection
was followed by significant elevations in the platelet counts of ck2bfl/fl
mice after 96 hours, whereas exogenous TPO did not sufficiently
elevate the platelet counts of ck2b2/2 mice and failed to prevent
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thrombocytopenia in these mice (Figure 1G). Of note, protein ex-
pression levels and surface coverage of the TPO receptor myelopro-
liferative leukemia virus oncogene were similar in platelets and MKs
(supplemental Figure 2). Platelet sialylation and hepatic TPO transcript
levels were comparable in ck2b2/2 and ck2bfl/fl mice as well (supple-
mental Figure 3), indicating that Ashwell-Morell receptor–dependent
platelet clearance is not affected by CK2b.
As revealed by immunohistological analysis, the BM of ck2b2/2
mice showed remarkable MK hyperplasia, reflected by a significantly
increased number of MKs within the BM (Figure 2A). Moreover,
asignificantnumberofck2b2/2BMMKsdisplayedsignsoffragmentation
with abrogated cellular demarcation. Further examination of MKs flushed
out of BM revealed a significantly reduced ploidy in ck2b-null MKs
with a significant reduction of 16N- and 32N-containing MKs
(Figure 2D), indicating that CK2b-deficiency results in the accumu-
lation of immature MKs. Although only a mild splenomegaly was
observed in ck2b2/2 mice (Figure 2C), after spleen immunostaining,
we found drastically increased extramedullary thrombopoiesis in
ck2b2/2mice, with distortion of splenic architecture strongly enriched
with GPIb-positive MKs (Figure 2B). Nevertheless, ck2b2/2 mice
displayed neither a modification of the hematopoietic stem and pro-
genitor cell compartment in the BM and spleen nor an excess of
hematopoietic progenitors in the peripheral blood (supplemental
Figure 4). Hematoxylin and eosin (H&E) staining of formalin-fixed,
paraffin-embedded spleens confirmed a markedly increased number
of MKs in the spleens from ck2b2/2mice (Figure 2B), whereas BM
and spleen fibrosis was not accelerated in CK2b-deficient mice
(supplemental Figure 5). GPIb and H&E staining of the lungs ruled
out any difference in the presence of MKs and platelets in the lung
circulation or parenchyma in ck2b2/2 mice as compared with wild-
typemice (supplemental Figure 6). Because ck2b2/2MKswere hardly
identifiable due to their altered morphology and demarcation from
surrounding cells, we analyzed the ultrastructure of BMMKs by TEM,
revealing impaired DMS formation and prominent granule-free zones

























































































































Figure 1. CK2b is strongly expressed in MKs and platelets, and CK2b deficiency results in macrothrombocytopenia, reduced platelet life span, and an increased
amount of immature reticulated platelets. (A) Representative image (bottom) and arithmetic means6 standard errors of the means (n5 6; top) of CK2b transcript levels in
platelets and kidneys from ck2bfl/fl and ck2b2/2 mice indicating a cell-specific knockout of CK2b in the MK/platelet lineage. (B) Representative immunoblots of CK2b protein
levels of MKs (top) and platelets (bottom) from ck2bfl/fl and ck2b2/2 mice (n 5 4) confirming a complete knockout of CK2b in the MK/platelet lineage. (C) Count and mean platelet
volume (MPV) of ck2bfl/fl (blue diamonds) and ck2b2/2 (gray diamonds) platelets (n5 24). Each diamond represents 1 individual mouse. (D) Endogenous survival of ck2bfl/fl (blue
trace) and ck2b2/2 (gray trace) platelets measured by the determination of the percentage of fluorescently labeled platelets in vivo at indicated time points after injection of DyLight
488 a-GPIX (n 5 6). (E) Flow cytometric quantification of the percentage of new, reticulated platelets as a percentage of total platelets in ck2bfl/fl and ck2b2/2 mice. Arithmetic
means 6 standard errors of the means (n 5 6) are shown. (F) TPO levels of ck2bfl/fl (blue bar) and ck2b2/2 (gray bar) mice. Arithmetic means 6 standard errors of the means
(n 5 15) are shown. (G) Platelet counts of ck2bfl/fl and ck2b2/2 mice before and 4 days after treatment with TPO (2 mg/animal per day). Arithmetic means6 standard errors of the
means (n 5 8) are shown. Unpaired Student t test in panels A and D-G. *P , .05; **P , .01.
Table 1. Glycoprotein surface expression of ck2bfl/fl and ck2b2/2
platelets
Platelet GP ck2bfl/fl ck2b2/2 P
GPIba 343 6 10 311 6 4 ,.01
GPV 145 6 3 121 6 2 ,.001
GPVI 66 6 3 62 6 2 .08
GPIX 175 6 5 145 6 1 ,.001
Integrin b1 147 6 5 141 6 7 .50
Integrin b3 184 6 4 182 6 3 .83
Results are expressed as mean fluorescence intensity 6 standard error of the
mean for 10 mice per group.
GPIba, glycoprotein Iba.
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of thesefindings, we next visualizedMKs in BM cryosections of intact
femora. Immunostaining clearly indicated that ck2b-null MKs had less
contact with BM sinusoids and displayed markedly increased fragmen-
tation (Figure 3B). To further study the role of CK2b in MK-dependent
platelet biogenesis, we performed in vitro proplatelet formation assays.
Accordingly, significantly fewer numbers of ck2b2/2 MKs formed
proplatelets (Figure 3C). For examination of these findings in vivo,
we analyzed proplatelet formation under steady-state conditions, visu-
alizing the BM in the mouse skull by using 2-photon intravital
microscopy (2P-IVM). 2P-IVM confirmed that ck2b2/2MKs undergo
premature ectopic fragmentation and are unable to efficiently release
proplatelets into the vascular sinusoids in vivo because 40.6% 6 7.6%
of the ck2b-deficient MKs had an altered morphology, appearing
fragmented as if the MKs were somewhat unstable, whereas only
11.5% 6 2.6% of the ck2bfl/fl MKs were fragmented (Figure 3D;
supplementalVideos1and2).As further revealedby2P-IVM,premature
platelet release by ck2b2/2MKs is probably caused by defective in vivo
proplatelet formation. Only 3.2% 6 2.9% of ck2b-null MKs produce
proplatelets in vivo compared with 8.5% 6 2.7% of ck2bfl/fl MKs,
indicating that CK2b is required for proplatelet formation and is a critical
regulator of thrombopoiesis (Figure3D).ToeliminateMKfragmentation
of ck2b2/2MKsas consequenceof increased apoptosis in these cells,we
determined caspase 3/7 activity. As illustrated in supplemental Figure 7,
caspase 3/7 activity in ck2b2/2MKswas similar to that in ck2bfl/flMKs.
Microtubules and tubulin polymerization are essential for platelet
structure and function. Because CK2b has been described as a critical
regulator of tubulin and microtubule architecture, we next exam-
ined tubulin structure and polymerization. Of note, a-tubulin filaments
appeared fragmented in many cultured ck2b2/2 MKs, indicating that
filament stability or polymerization were affected in the absence of
CK2b (Figure 4A). Along those lines, treatmentwith themicrotubule-
stabilizing toxin, paclitaxel, resulted in an increase of polymerized
b-tubulin in ck2bfl/fl, whereas ck2b2/2 platelets failed to stabilize
polymerized tubulin (Figure 4B), pointing to a critical role of CK2b in
platelet microtubule stability. Presumably as a result of impaired
tubulin polymerization, ck2b2/2 platelets also showed significantly
less EB3 binding (Figure 4C).
Because we know from other cell types that EB3 may act as an
important linker between polymerized microtubules and the regula-
tion of internal Ca21 stores,8 we next aimed to elucidate the impact
of CK2b-driven tubulin polymerization on intracellular Ca21 release
and subsequent Ca21-dependent platelet activation. To discriminate
between intracellular Ca21 store release and Ca21 influx from
extracellular space, we used spectrofluorometry to determine the
activation-dependent changes of [Ca21]i in the absence or presence of
extracellular Ca21 (Figure 5A-B). Before stimulation, the cytosolic
Ca21 concentration was similar. By comparison, in the presence and in
the absence of extracellular Ca21, ck2b2/2 platelets displayed a sig-
nificantly blunted [Ca21]i increase in response to stimulationwith CRP
or thrombin, pointing to an impaired intracellular regulation of
cytosolic Ca21 release in ck2b-null platelets. IP3 production occurs
due to the activation of phospholipase C (PLC) induced by thrombin
downstream of G protein–coupled signaling or after stimulation of the
tyrosine kinase–linked collagen receptor glycoprotein VI (GPVI) by
collagen or CRP.32 To test if the decreased intracellular Ca21 release in
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Figure 2. Ck2b2/2 mice display BM MK hyperplasia and an upregulation of extramedullary thrombopoiesis. (A) Representative images of GPIb immunostaining of BM
sections from 2-month-old ck2bfl/fl and ck2b2/2 mice (left). Quantification of ck2bfl/fl and ck2b2/2 BM MKs per visual field. Arithmetic means 6 standard errors of the means
(n5 6; right) are shown. (B) Representative images of GPIb immunostaining of spleen sections from 6-month-old ck2bfl/fl and ck2b2/2 mice (left). Quantification of ck2bfl/fl and
ck2b2/2 spleen MKs per visual field. Arithmetic means 6 standard errors of the means (n 5 6; right) are shown. (C) Representative H&E staining of spleen sections from
6-month-old ck2bfl/fl and ck2b2/2 mice (left). Arithmetic means 6 standard errors of the means (n 5 8; right) of relative spleen weight in ck2bfl/fl and ck2b2/2 mice. (D) Ploidy
histogram of ck2bfl/fl and ck2b2/2 MKs (left) and arithmetic means 6 standard errors of the means (n 5 6; right) are shown. Unpaired Student t test. *P , .05; **P , .01.














































































Figure 3. Ck2b2/2 MKs exhibit abnormal ultrastructure, resulting in premature MK fragmentation in the BM and impaired proplatelet formation. (A) Representative TEM
images of ck2bfl/fl (left) and ck2b2/2 (middle and right) MKs in the BM showing increased fragmentation, decreased presence of demarcation membranes, and large granule-free zones
on ck2b deficiency. Upper, overview (bar represents 3 mm). Lower, detail (bar represents 1 mm). (B) Representative confocal microscopy images of immunostained BM sections (left)
and arithmetic means 6 standard errors of the means (n 5 6; right) of MK fragmentation in the BM of ck2bfl/fl and ck2b2/2 mice (n 5 6). Green, MKs (GPIb); red, sinusoids (CD105);
gray, nuclei (49,6-diamidino-2-phenylindole). Bar represents 20 mm. (C) Quantification of the percentage of proplatelet-forming fetal liver cell–derived MKs from ck2bfl/fl and ck2b2/2mice
in vitro on day 4 of culture. Ck2bfl/fl and ck2b2/2 MKs extending proplatelets were counted 18 hours after bovine serum albumin gradient and expressed as percentage of total MKs.
Arithmetic means6 standard errors of the means (n5 10) are shown. (D) 2P-IVM revealing MK instability and reduced proplatelet formation in ck2b2/2MKs in vivo. Platelets and MKs
were stained with anti-GPIX antibodies (green), and the vessel lumen was labeled using fluorescein isothiocyanate-bovine serum albumin and anti-CD105 antibodies (red). Proplatelet-
forming MKs (white arrows indicated proplatelets) were counted, and the ratio per mouse was assessed (n5 5). MK morphology was categorized by a blinded experimenter in normal
and fragmented (blue arrows). Representative images from the BM of ck2bfl/fl and ck2b2/2 MKs (left) and arithmetic means 6 standard errors of the means (n 5 5; right) of
proplatelet-forming MKs and of MKs with altered morphology are shown. Bar represents 50 mm. Unpaired Student t test in panels C and D. *P , .05; **P , .01.
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production, we investigated whether IP3 production or activation of
PLC is regulated by CK2b. Neither activation-dependent myo-inositol
1 phosphate production, reflecting the levels of the unstable IP3, nor
PLC phosphorylation were significantly affected in ck2b2/2 platelets
(supplemental Figure 8). However, as revealed by light pulse-triggered
activation of caged IP3, the IP3-dependent release of Ca
21 from
intracellular stores was significantly blunted in ck2b-deficient platelets
(Figure 5C), pointing to CK2b-sensitive regulation of IP3R activation
on platelet stimulation. The total expression of platelet IP3Rs and
phosphorylation of IP3R1, mainly located in the ER of platelets, were
comparable (supplemental Figure 9). However, the abundance of
IP3R1 bound to the fraction of polymerized tubulin was significantly
diminished in ck2b2/2 platelets (supplemental Figure 9).
To assess the functional significance of impaired IP3R activation and
the corresponding defective [Ca21]i increase in ck2b
2/2 platelets, we
determined platelet degranulation, integrin aIIbb3 activation, and
aggregation after platelet stimulation via ITAM-coupled (CRP) or
G-protein–coupled (thrombin) receptors. As quantified by flow
cytometry and luminescence analysis, the activation-dependent
secretion of platelet a and dense-granules after stimulation with low
and intermediate concentrations of CRP or thrombin were sig-
nificantly decreased in ck2b2/2 platelets (Figure 5D-E). Moreover,
integrin aIIbb3 activation, which is required for fibrinogen binding,
was significantly diminished in ck2b2/2 platelets after stimulation
with CRP or thrombin (Figure 5F). Light transmission aggregometry
was used to explore whether impaired degranulation and integrin
aIIbb3 activation would translate into reduced activation-dependent
platelet aggregation. After stimulation with increasing concentrations
of CRP or thrombin, aggregation of ck2b-null platelets was signi-
ficantly blunted (Figure 5G). Defective degranulation, integrin aIIbb3
activation, and aggregation in ck2b2/2 platelets were overcome by
high agonist concentrations. Interestingly, as illustrated in supple-
mental Figures 10-14, comparablewith ourfindings inmurine ck2b2/2
platelets, the treatment of mature murine and human platelets with the
CK2 inhibitors (E)-3-(2,3,4,5-tetrabromophenyl)acrylic acid (TBCA)
and CX-4945 significantly affected platelet Ca21 influx, secretion, and
aggregation in response to CRP.
A further series of experiments elucidated the consequences
of impaired activation of ck2b-deficient platelets for platelet adhesion
to collagen-coated surfaces under flow at high arterial shear rates
(1700 s21). Although ck2bfl/fl platelets rapidly adhered to collagen
and formed stable thrombi, thrombus formation by ck2b2/2 platelets
was significantly decreased because the thrombus surface coverage
was reduced by;71% (Figure 6A). Because Ca21-dependent platelet
activation may contribute to pathological thrombus formation in vivo,
we next assessed the time to occlusion of mesenteric arterioles and
carotid arteries due to thrombus formation after ferric chloride (FeCl3)-
induced injury in mice with a platelet-specific deletion of CK2b.
Arterial thrombotic occlusion was significantly delayed and decreased
in ck2b2/2 mice after FeCl3-triggered vascular injury of mesenteric
arterioles (Figure 6B). Seventy-five percent of the ck2b2/2mice failed
to form an occlusive thrombus within 25 minutes, whereas in ck2bfl/fl
mice, the mean time to thrombotic vascular occlusion was
;14 minutes. Ck2b2/2 mice were similarly protected from acute
arterial thrombosis after FeCl3-induced injury of carotid arteries.
Whereas all ck2bfl/fl mice displayed a rapid and complete vascular
occlusion, the time to occlusion was significantly prolonged in ck2b2/2
mice.Nodiscontinuationofbloodflowwas found in42%of theck2b2/2
mice due to the absence of thrombotic occlusion at the end of the
20-minute observation period (Figure 6C). Real-time imaging of
thrombus formation underflow thatwas achieved by capturing images
of fluorescently labeled platelets indicated a consistent and gradual
increase in fluorescence intensity from the deposited ck2bfl/fl platelets
(Figure 6D). With platelets from the ck2b2/2 mice, the slope of
fluorescence increase was diminished, and the time traces pointed to a
slow and insufficient thrombus buildup. These findings from both in
vitro and in vivo models of arterial thrombosis indicate that CK2b-
mediated activation of IP3R is required for efficient platelet activa-
tion underlying thrombotic vascular occlusion. To test whether the
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Figure 4. CK2b is essential for microtubule archi-
tecture and tubulin polymerization as well as EB3
binding to polymerized tubulin. (A) Representative
immunofluorescence confocal microscopy images of
cultured fetal liver–derived ck2bfl/fl and ck2b2/2 MKs.
a-Tubulin staining appears fragmented in Ck2b2/2
MKs undergoing proplatelet formation. Bar represents
20 mm (overview) and 5 mm (detail). (B) Representative
immunoblots of 3 independent experiments of free
and polymerized tubulin in ck2bfl/fl and ck2b2/2 platelets
(n 5 3) in the absence and presence of paclitaxel
(10 mM) in supernatant (sn) and pellet (p). (C) Represen-
tative immunoblots of EB3 bound to polymerized tubulin in
ck2bfl/fl and ck2b2/2 platelets (n 5 3) after treatment with
paclitaxel (10 mM) in supernatant (sn) and pellet (p).
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Figure 5. CK2b is a critical regulator of platelet IP3 -triggered Ca
21 release from internal stores with subsequent extracellular Ca21 influx, resulting in impaired
granule secretion, integrin aIIb b3 activation, and aggregation in ck2b-null platelets. (A) Representative tracings of Fura-2-fluorescence reflecting the cytosolic Ca
21
concentration [Ca21]i (right) and arithmetic means of maximal Δ[Ca21]i 6 standard deviations (n 5 6; left) of ck2bfl/fl (blue line) and ck2b2/2 (gray line) platelets before and
after stimulation with CRP (5 mg/ml) and thrombin (20 mU/ml) in the absence (0.5 mM EGTA) of extracellular Ca21. (B) Representative tracings of Fura-2-fluorescence
reflecting the cytosolic Ca21 concentration [Ca21]i (right) and arithmetic means of maximal Δ[Ca21]i 6 standard deviations (n5 6; left) of ck2bfl/fl (blue line) and ck2b2/2 (gray
line) platelets before and after stimulation with CRP (5 mg/ml) and thrombin (20 mU/ml) in the presence (1 mM Ca21) of extracellular Ca21. (C) Representative tracings
of Fura-2-fluorescence reflecting cytosolic Ca21 concentration [Ca21]i (lower) and arithmetic means of maximal Δ[Ca21]i 6 standard deviations (n 5 6; upper) of ck2bfl/fl (blue
line) and ck2b2/2 (gray line) platelets before and after stimulation with IP3 (2.5 mM). The cytosolic Ca
21 concentration before and after flash photolysis (365 nm) in the
absence of IP3 was measured as a control (tracing not shown). (D) Flow cytometric analysis of P-selectin exposure reflecting a-granule release in ck2b
fl/fl (blue bars) and
ck2b2/2 (gray bars) platelets in response to increasing concentrations of CRP (in micrograms per milliliter) or thrombin (in microunits per milliliter). Arithmetic means 6 standard
errors of the means (n 5 6) are shown. (E) Luminescence analysis of ATP release reflecting the secretion of dense granules in response to increasing concentrations of CRP
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we measured tail bleeding time. As illustrated in Figure 6E, ck2b2/2
mice showed a minor bleeding tendency without a significantly pro-
longed bleeding time as compared with ck2bfl/fl mice (Figure 6E).
As a logical extension of our findings that CK2b can modulate
arterial thrombosis, we investigated the impact of platelet CK2b on
responses and outcome after ischemic stroke. Mice with a platelet-
specific knockout of ck2b were studied in the tMCAO model. As
determined by 2,3,5-triphenyltetrazoliumchloride staining (Figure 7A),
brain infarct volumes were significantly reduced in ck2b2/2 mice
24 hours after tMCAO. Moreover, the platelet-specific CK2b de-
ficiency resulted in a significantly decreased Bederson score reflecting
the loss of global neurological function and a significantly improved
grip test, assessing motor function and coordination. Collectively,
these indicators demonstrate that the marked reduction of infarct
volumes in ck2b2/2 mice was functionally relevant (Figure 7B).
Histological analysis of brain sections revealed significantly less
thrombotic-occludedvessels in ck2b2/2mice (Figure 7D).Toconfirm
the protective effect of a genetic CK2b knockout on ischemic brain
infarct development, magnetic resonance imaging was performed on
living mice. As illustrated by serial T2-weighted magnetic resonance
imaging, hyperintense ischemic brain infarcts weremarkedly reduced in
ck2b2/2mice after tMCAO, a protective effect that was sustained over
7 days (Figure 7C-E). Ck2b2/2 mice further displayed significantly
improved outcomes because CK2b deficiency resulted in increased
survival 7 days after tMCAO. As illustrated by the Kaplan-Maier curve,
53.8% of ck2b2/2 mice survived the 7-day observation period after
tMCAO, whereas 82.5% of the ck2bfl/fl mice died within 7 days after
ischemic stroke. Notably, we found no intracranial hemorrhages in
ck2b2/2mice after tMCAO (Figure 7F).
Discussion
The results of the present study disclose a key role for the protein kinase
CK2 in the tightly regulated signaling processes in MKs and platelets.
CK2b is required for thrombopoiesis and Ca21-triggered platelet ac-
tivation and, by the same token, contributes to acute arterial thrombotic
occlusion and consecutive ischemic diseases, such as acute myocardial
infarction and ischemic stroke, the leading causes of death and per-
manent disability in industrialized countries.18
Ck2b2/2 mice suffer from severe macrothrombocytopenia result-
ing fromdefective thrombopoiesis due to prematureMK fragmentation
with prematurely released, enlarged platelets and crippled proplatelet
formation, potentially driven by significantly altered tubulin polymer-
ization and impaired microtubule assembly. Similar macrothrombo-
cytopenia was observed in mice lacking other regulators of platelet
tubulin organization and microtubule dynamics, such as Filamin A
(FlnA)33 or the GTPases, Rac1/Cdc42.34 Similar to Rac1/Cdc42-null
platelets or platelets with a genetic ablation of FlnA, ck2b2/2 platelets
harbor less vWF receptor complex abundance than ck2bfl/fl platelets
(Table 1). FlnA cross-links actin filaments, connecting vWF receptor
GPIb-IX-V to the platelet cytoskeleton, and interacts with Syk, reg-
ulating platelet ITAM-mediated receptor signaling and function.33,35
Similar to ck2b2/2 platelets, FlnA-null platelets are relatively insensi-
tive to activation.35 However, neither FlnA expression (supplemental
Figure 15) nor Syk phosphorylation (supplemental Figure 8C) were
significantly affected inCK2b-deficient platelets. Double knockout of
2 additionalmajor regulators of tubulin organization,Rac1 andCdc42,
resulted in altered MK morphology and uncontrolled MK fragmen-
tation,34 similar to ck2b2/2. Nevertheless, the activity of Rac1 and
Cdc42 was unaffected in ck2b2/2 platelets (supplemental Figure 16),
excluding Rac1/Cdc42 as potential downstream targets of CK2 in
MKs or platelets.
In vivo visualization of thrombopoiesis in MK/platelet-specific
knockout of CK2b revealed significant alterations in the MK
cytoskeleton, resulting in premature ectopic M-fragmentation and
severely affected proplatelet formation. During MK maturation,
polymerization of microtubules assembled from a- and b-tubulin
heterodimers is essential for maintaining reorganization of the MK
cytoskeleton underlying proplatelet formation and subsequent
platelet production.4,5 Recently, tubulin has been reported as a
direct target of CK2.25,36 Accordingly, CK2 directly binds tubulin
heterodimers, thus strongly stabilizing microtubule polymerization.23
Even the microtubule-stabilizing agent paclitaxel failed to stabilize
polymerized tubulin and to prevent depolymerization of b1-tubulin in
ck2b2/2MKs.b1-tubulin, restrictively expressed in theMK lineage,37
is the major tubulin isotype in platelets and is indispensable for
microtubule assembly and thus platelet production in MKs.6 Loss of
b1-tubulin in mice and loss-of-function b1-tubulin polymorphisms in
humans both result in severely impaired proplatelet formation with
significant macrothrombocytopenia due to deformed microtubules,
premature MK fragmentation, and release of large platelets,6,7,37,38 a
phenotypevirtually identical to thedeletionofCK2b in theMK/platelet
lineage reported in this article. Due to the abrogated tubulin poly-
merization, binding of EB3 to polymerizingmicrotubuleswas impaired
in ck2b2/2 platelets andMKs. Accordingly, proplatelet maturation and
platelet release inMKsmay be affected byCK2b deficiency. However,
despite the analogy between loss of b1-tubulin and CK2b in the MK/
platelet lineage for platelet biogenesis, the phenotype regarding platelet
activation is different. As reported recently,37 even if aggregation ofb1-
tubulin2/2 platelets was blunted after stimulation with a low dose of
thrombin, thrombus formation in mice lacking platelet b1-tubulin was
not as strongly impaired as in ck2b2/2 mice, suggesting that CK2 defi-
ciency affects additional mechanisms in platelets that are essential for
activation and thrombus formation beyondmodulating plateletb1-tubulin.
Ck2b-deficient mice compensate for defective proplatelet forma-
tion and insufficient thrombopoiesis by increasing BMmegakaryopoi-
esis and extramedullary thrombopoiesis. Similar to what was observed
in other mice with impaired platelet production as a result of abolished
microtubule assembly,39 splenomegalywas onlymild in ck2b2/2mice
despite the profound spleen MK hyperplasia. The reticuloendothelial
system in the liver and spleen clears platelets from the circulation due to
altered cellular morphology34 or platelet apoptosis.40,41 In theory, CK2
could suppress apoptosis by the stimulation of PI3K/Akt signaling,42
direct interactionwith theBcl-2-associated death promoter (BAD),43 or
decreased susceptibility of caspase substrates, suchas theBH3 interacting-
domain death agonist (BID), to caspase cleavage.36,44 However,
phosphorylation of Akt and its downstream target, BAD, both
critical elements in prosurvival signaling of platelets,45 were not
significantly affected in ck2b2/2 platelets (supplemental Figure 17).
Figure 5 (continued) (in micrograms per milliliter) or thrombin (in microunits per milliliter). Representative ATP release tracings of ck2bfl/fl (blue lines) and ck2b2/2 (gray lines) mice
are shown (n5 6). (F) Flow cytometric analysis of aIIbb3 integrin activation in ck2b
fl/fl (blue bars) and ck2b2/2 (gray bars) platelets in response to increasing concentrations of CRP
(in micrograms per milliliter) or thrombin (in microunits per milliliter). Arithmetic means6 standard errors of the means (n5 6) are shown. (G) Light transmission aggregometry after
stimulation with increasing concentrations of CRP (in micrograms per milliliter) or thrombin (in microunits per milliliter). Representative aggregation tracings of ck2bfl/fl (blue lines) and
ck2b2/2 (gray lines) platelets are shown (n 5 4). Unpaired Student t test in panels A-D. *P , .05; **P , .01.
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Besides the critical role ofCK2 in thrombopoiesis, the present study
revealed that CK2 is essential for the activation-dependent [Ca21]i
increase via the regulation of IP3-dependent Ca
21 release from internal
stores. IP3 is generated by several PLC isoforms and mediates intra-
cellular Ca21 release by activating IP3Rs located on the ER.
13,46
Although platelet activation by collagen and CRP culminates in
PLCg2-activation downstream of GPVI, stimulation with thrombin
activates PLCb via G-protein–coupled signaling.47 IP3R function is
presumably regulated in part by the modulation of IP3R expression,
clustering, and phosphorylation.8,13 Cyclic nucleotide cyclic adenosine
monophosphate (cAMP) mediates its inhibitory effects on platelet
activation potentially by phosphorylating IP3Rs with subsequent
inhibition of intracellular Ca21 release.13,46 However, even though
CK2 has recently been identified as a negative regulator of cAMP
generation,48 neither cAMP levels (data not shown) nor phosphor-
ylation of IP3R1, mainly expressed in the ER of platelets, were sig-
nificantly affected in ck2b2/2 platelets (supplemental Figure 9).
Total IP3R protein abundance was similar in ck2b
2/2 platelets and
ck2bfl/fl platelets (supplemental Figure 9). The major regulators of
IP3-induced Ca
21-signaling also includes microtubule-associated
EB3, which directly interacts with the S/TxIP motif within IP3Rs,
thus facilitating IP3R clustering and activation.
8 Because ck2b2/2
platelets display blunted tubulin polymerization as well as abrogated































































































Figure 6. Ck2b deficiency results in significantly reduced platelet adhesion and thrombus stability under high arterial shear rates as well as abrogated thrombotic
vascular occlusion in vivo, whereas primary hemostasis is not significantly affected. (A) Flow chamber analysis of platelet adhesion to collagen and thrombus
formation in vitro under high arterial shear rates. Whole blood from ck2bfl/fl and ck2b2/2 mice was perfused over a collagen-coated surface for 5 minutes at a shear rate of
1700 s21. Arithmetic means 6 standard errors of the means (n 5 6; right) and representative phase contrast images (left) of surface coverage are shown. Bar represents
50 mm. (B) Time to arterial occlusion after FeCl3-induced injury of mesenteric arterioles (right, n 5 12) and representative images of occlusive in vivo thrombus formation after
0, 10, and 20 minutes (left) in ck2bfl/fl and ck2b2/2 mice. Each dot represents 1 individual mouse. Bar represents 50 mm. (C) Representative images of in vivo thrombus
formation after 0, 2.5, 5, 10, and 20 minutes (left) and time to arterial occlusion after FeCl3-induced injury of carotid arteries (upper right, n 5 12) and representative
immunohistological H&E staining (lower right) of occlusive in vivo thrombus formation after 7 minutes in ck2bfl/fl and ck2b2/2 mice. Each dot represents 1 individual mouse.
Bar represents 100 mm. (D) Arithmetic means 6 standard errors of the means (n 5 6) of integrated fluorescence intensity of adherent platelets after perfusion of whole blood
from ck2bfl/fl (blue dots) and ck2b2/2 (gray dots) mice over a collagen-coated surface representing thrombus growth in vitro over 5 minutes. (E) Tail bleeding time measured
after amputating the tail tip of ck2bfl/fl and ck2b2/2 mice. Each dot represents 1 individual mouse (n 5 36). Unpaired Student t test in panels A-E. **P , .01.
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disordered IP3R clusteringmay contribute to impaired Ca
21 release
from intracellular stores in ck2b2/2 platelets. These findings are in
line with previous studies reporting that the disruption of the
cortical microtubule system results in abrogated intracellular Ca21
release.49
In platelets, IP3-mediated Ca
21 release from the ER triggers Ca21
entry from the extracellular compartment, potentiating the [Ca21]i
increase and thus facilitating subsequent platelet activation and
aggregation with consecutive thrombus formation. Intracellular Ca21
store depletion is sensed by STIM1, which activates store-operated
Ca21 entry via the pore-forming Ca21 release–activated channel
Orai1.47 Similar to ck2b2/2 mice, animals expressing mutant Stim1
displayed macrothrombocytopenia, MK hyperplasia, and decreased
platelet life span, pointing to an important role of intracellular Ca21
regulation in MKs/platelets for thrombopoiesis.32 In STIM1-deficient
platelets, the Ca21 response on platelet activation with CRP and
thrombin is blunted,47 mimicking the phenotype of ck2b2/2 platelets.
However, STIM1 expression was similar in ck2b-null platelets and
wild-type platelets (supplemental Figure 18).
Although CK2 is readily detected in platelets, its role in platelet
function remained ill defined. CK2 is constitutively active in platelets,
suggesting that its effects are tightly modulated by phosphatases.31
According to pharmacological studies using CK2 inhibitors, CK2 may
play a role in platelet activation.50-52 However, the precise role of CK2
in platelet function and arterial thrombosis has remained elusive due to
the lack of selectivity of the reagents available to target CK2 and its
subunits. Pharmacological approaches suggested that CK2 modu-
lates PI3K-Akt–dependent signaling in platelets.51,52 In our genetic
knockout approach, we did not find evidence for CK2-dependent ac-































































































Figure 7. Ck2b2/2 mice are protected from ischemic stroke in vivo and display less thrombotic cerebral vascular occlusions with a significantly better
neurological outcome and survival after stroke. (A) Representative images of 3 corresponding coronal sections of 2,3,5-triphenyltetrazolium chloride–stained brains from
ck2bfl/fl and ck2b2/2 mice 24 hours after tMCAO (left). Arithmetic means6 standard errors of the mean (n 5 11-12) of brain infarct volumes in ck2bfl/fl (blue bar) and ck2b2/2
mice (gray bar) 24 hours after tMCAO (right). (B) Bederson score reflecting global neurological defects (0 indicates best, 5 indicates worst; left) and grip test indicating motor
functional and coordination deficits (0 indicates worst, 5 indicates best; right) assessed 24 hours after tMCAO. Each dot represents 1 individual mouse. (C) Representative
coronal T2-weighted magnetic resonance imaging images of hyperintense ischemic brain infarct lesions of ck2bfl/fl and ck2b2/2 mice at day 1 and day 7 (infarct maturation)
after tMCAO (n 5 3-7/group). Hypointense areas (reflecting intracerebral hemorrhage) were not observed. (D) Determination of thrombosis index by quantification of
thrombotic occluded vs nonoccluded vessels within the ischemic hemisphere 24 hours after tMCAO. Arithmetic means 6 standard errors of the means (n 5 5, right) and
representative images (left) of H&E-stained cryosections are shown. Bar represents 100 mm. (E) Arithmetic means6 standard errors of the means (n5 6) of infarct volume in
ck2bfl/fl and ck2b2/2 mice 7 days after tMCAO (infarct maturation). (F) Analysis of survival of ck2bfl/fl (blue line) and ck2b2/2 (gray line) mice 7 days after ischemic stroke
(n 5 13-17). Student t test in panels A-D and log-rank (Mantel-Cox) analysis in panel F. **P , .01.
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(supplemental Figure 17). We do not have a precise explanation for
these apparent discrepancies other than the limited selectivity of the
pharmacological CK2 inhibitors used.53-55 For example theCK inhibitor
5,6-dichloro-1-(b-D-ribo-furanosyl) benzimidazole, used in some of
previous studies on platelets, inhibits both CK2 and CK1 isoforms as
well as other cellular targets.50 In the present study, we were able to
define CK2b as a critical regulator of Ca21-triggered platelet activation
using MK/platelet-specific deletion of the CK2 regulatory b-subunit.
Similar to our observations in ck2b-null platelets, treatment of murine
and human platelets with TBCA and CX-4945 significantly affected
platelet Ca21 influx, secretion, and aggregation in response to CRP
(supplemental Figure 10-14) without affecting Akt phosphorylation
(supplemental Figure 19), indicating that CK2 is crucial for GPVI-
dependent signaling without involving Akt-dependent intracellu-
lar pathways. Because TBCAandCX-4945 sufficiently blocked platelet
Akt phosphorylation after activationwith the Par-4 agonist AYPGKF or
2-methylthioadenosine diphosphate (2-MeSADP), we speculate that
CK2 may play a role in modifying Akt signaling downstream of
PAR-4 or the purinergic receptor P2Y12. However, further studies
will be necessary to clarify the role of CK2 in signaling downstream
of purinergic receptors, in particular P2Y12. Inhibition of CK2 in
thrombin-driven platelet activation did not affect Akt phosphorylation
(supplemental Figure 19), pointing to Akt-independent CK2 signaling
in response to platelet stimulation with thrombin. Nevertheless,
consistent with thefindings byAmpofo et al,56 using the CK2 inhibitor
CX-4945, we show for the first time that CK2b is an essential player
in thrombopoiesis and arterial thrombosis in vivo.
According to our observations, activation-dependent Ca21 release
is mainly under the control of the constitutively active CK2. As a
consequence of the severely impairedCa21 response, platelet adhesion,
secretion, and integrin aIIbb3 activation are significantly abolished in
ck2b2/2platelets. Themarkedknockdownof integrinaIIbb3 activation
in response to thrombin or CRP in platelets lacking CK2b paralleled a
deficit in the ability of these platelets to undergo aggregation at
submaximal agonist concentrations. Increasing the agonist concentra-
tions dissipated the differences between ck2b2/2 and ck2bfl/fl platelets,
indicating that other signaling processes are able to bypass intracellular
platelet pathways that are controlled by CK2. The defective activation
of ck2b2/2 platelets in vitro translated into a significantly blunted
arterial occlusive thrombus formation in vivo, revealing CK2b to be a
potential drug target for antithrombotic therapy, because tail bleeding
time, partially reflecting primary hemostasis, was not significantly
affected. Platelet-specific deletion of CK2b in mice resulted in a
significant reduction of intravascular thrombosis and a profound
protection against ischemic neuronal damage, with significantly
improved neurological outcomes and survival 7 days after ischemic
stroke. However, it is important to note that the data obtained in the
murine tMCAO model cannot be extrapolated to humans without
reservations due to possible differences in the underlying pathome-
chanisms.47 Of note, not only does CK2 regulate platelet-triggered
thrombus formation, but also a considerable number of proteins
involved in the coagulationcascadehavebeen identifiedas substrates of
CK2.57 CK2 phosphorylates several coagulation factors, tissue factor
pathway inhibitor, and fibrinogen, suggesting that CK2 may also
directly interfere with plasmatic coagulation.57,58
In conclusion, using MK/platelet-specific deletion of the CK2
regulatory b-subunit, we provide strong evidence that CK2 is
essential for platelet biogenesis and activation. CK2 is critically
required for the regulation of MK maturation and fragmentation,
both underlying sufficient proplatelet formation, due to the fact that
tubulin polymerization is controlled by CK2. Further, CK2 was
identified as a major player in the activation-dependent [Ca21]i
increase by facilitating the release from stores as well as Ca21-
dependent platelet activation and arterial thrombus formation
in vivo. These findings may have important implications for the
development of novel antithrombotic therapies because the absence of
CK2b provides profound protection from occlusive arterial
thrombosis and ischemic stroke in vivo with substantially improved
outcomes. Further, this study may deepen the understanding of the
(patho-)physiological mechanisms underlying proplatelet formation,
thrombopoiesis, and the development of macrothrombocytopenia.
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